SLNO
SOLENO THERAPEUTICS INCCompany Information
- Company Name
- SOLENO THERAPEUTICS INC
- CIK
- CIK0001484565
- Category
- Large accelerated filer
- Ticker: Exchange
- SLNO: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- SLNO
SEC filing data through
Insider Sentiment
- Last purchase
- 2023-09-28
- Last sale
- 2026-03-27
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 1,334,187
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 54,043,395
- Shares outstanding
- 52,091,047
- Ownership
- 103.75%
Earnings Market Reaction
- Filing date
- 2026-05-07
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 133 | 70 | 247 | 76 | 81 | 88 | 48 | 57 | 43 | 170 | 52 | 19 | ||||||
| Short Term Investments | - | - | - | - | - | - | - | - | 107 | - | - | - | ||||||
| Marketable Securities Current | 123 | 235 | 252 | 210 | 209 | 204 | 208 | 209 | - | - | - | - | ||||||
| Accounts Receivable Net Current | 47 | 28 | 26 | 25 | - | - | - | - | - | - | - | - | ||||||
| Inventory Net | 17 | 15 | 7 | 2 | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 6 | 7 | 4 | 3 | 19 | 2 | 1 | 1 | 2 | 2 | 1 | 1 | ||||||
| Assets Current | 326 | 356 | 535 | 317 | 309 | 294 | 258 | 268 | 151 | 171 | 54 | 20 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 4 | 2 | 2 | 2 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 1 | ||||||
| Intangible Assets Net Excluding Goodwill | 4 | 5 | 5 | 6 | 6 | 7 | 7 | 8 | 8 | 9 | 9 | 10 | ||||||
| Long Term Investments | - | - | - | - | - | - | - | - | 9 | - | - | - | ||||||
| Marketable Securities Noncurrent | 273 | 201 | 57 | 7 | 0 | 27 | 28 | 28 | - | - | - | - | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 608 | 564 | 600 | 332 | 318 | 331 | 297 | 304 | 169 | 181 | 64 | 31 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 12 | 12 | 8 | 6 | 5 | 9 | 6 | 4 | 8 | 3 | 3 | 3 | ||||||
| Employee Related Liabilities Current | 6 | 10 | 7 | 6 | 4 | 5 | 3 | 2 | 1 | 3 | 1 | 1 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Interest Payable Current | - | - | - | 0 | 0 | - | - | - | - | - | - | - | ||||||
| Asset Acquisition Contingent Consideration Liability Current | 14 | 20 | - | - | - | - | - | - | - | - | - | - | ||||||
| Other Liabilities Current | 25 | 18 | 17 | 6 | 3 | 5 | 3 | 1 | 2 | 2 | 1 | 1 | ||||||
| Liabilities Current | 58 | 61 | 33 | 21 | 16 | 19 | 15 | 9 | 13 | 12 | 29 | 9 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Asset Acquisition Contingent Consideration Liability Noncurrent | - | - | 19 | 19 | 18 | 15 | 14 | 14 | 12 | 12 | 10 | 9 | ||||||
| Long Term Debt Noncurrent | 50 | 50 | 50 | 50 | 50 | 50 | - | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 3 | 2 | 2 | 2 | 2 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Liabilities Noncurrent | 1 | 1 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | ||||||
| Liabilities | 113 | 114 | 105 | 92 | 86 | 86 | 32 | 23 | 25 | 23 | 40 | 19 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 898 | 881 | 969 | 741 | 728 | 697 | 660 | 601 | 441 | 434 | 288 | 267 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -2 | 0 | 0 | 0 | 0 | 0 | 1 | -0 | -0 | - | -0 | - | ||||||
| Retained Earnings Accumulated Deficit | -400 | -431 | -475 | -501 | -496 | -452 | -396 | -320 | -298 | -276 | -265 | -254 | ||||||
| Stockholders Equity | 496 | 450 | 495 | 240 | 232 | 245 | 265 | 281 | 143 | 158 | 23 | 12 | ||||||
| Liabilities And Stockholders Equity | 608 | 564 | 600 | 332 | 318 | 331 | 297 | 304 | 169 | 181 | 64 | 31 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 52 | 52 | 54 | 50 | 49 | 46 | 41 | 38 | 33 | 32 | 15 | 9 | ||||||
| Shares Outstanding | 52 | 52 | 54 | 50 | 49 | 46 | 41 | 38 | 33 | 32 | 15 | 9 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialSOLENO THERAPEUTICS INC (SLNO) — SEC Financial Statements & Analysis
SOLENO THERAPEUTICS INC (SLNO) is a pharmaceutical preparations company, incorporated in DE. SOLENO THERAPEUTICS INC trades on Nasdaq as: SLNO. SOLENO THERAPEUTICS INC (SLNO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-07. Based on that filing, On profitability, SOLENO THERAPEUTICS INC posts a gross margin of 98.63%, an operating margin of 30.33%, a net margin of 33.55%, a Return on Equity (ROE) of 26.27%, a Return on Assets (ROA) of 20.64%, and a Return on Invested Capital (ROIC) of 26.93%. Per share, it reports EPS of $1.84, diluted EPS of $1.80, free cash flow per share of $2.02, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -148.24% year-over-year and EPS growth of -142.77% year-over-year. On the balance sheet, it maintains a current ratio of 5.62x, a quick ratio of 5.22x, working capital of $268.33M, a debt-to-equity ratio of 0.23x, a debt ratio of 0.19, an interest coverage ratio of 15.99x, free cash flow of $105.42M (TTM), and net debt of $-83.16M. Figures sourced from SEC EDGAR.
- EPS TTM
- $1.84
- ROE TTM
- 26.27%
- ROA TTM
- 20.64%
- Debt To Equity
- 0.23x
- Free Cash Flow TTM
- $105.42M
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is SOLENO THERAPEUTICS INC in?
SOLENO THERAPEUTICS INC (SLNO) operates in the Pharmaceutical Preparations industry.
What exchange does SLNO trade on?
SOLENO THERAPEUTICS INC (SLNO) trades on the Nasdaq.
Where is SOLENO THERAPEUTICS INC incorporated?
SOLENO THERAPEUTICS INC is incorporated in DE.
When was SOLENO THERAPEUTICS INC (SLNO)'s most recent SEC filing?
SOLENO THERAPEUTICS INC (SLNO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-07.
What is SLNO's EPS (earnings per share)?
SOLENO THERAPEUTICS INC (SLNO)'s trailing twelve month EPS is $1.84 as of 2026-03-31.
What is SLNO's ROE (return on equity)?
SOLENO THERAPEUTICS INC (SLNO)'s trailing twelve month Return on Equity (ROE) is 26.27% as of 2026-03-31.
What is SLNO's ROA (return on assets)?
SOLENO THERAPEUTICS INC (SLNO)'s trailing twelve month Return on Assets (ROA) is 20.64% as of 2026-03-31.
What is SLNO's ROIC (return on invested capital)?
SOLENO THERAPEUTICS INC (SLNO)'s trailing twelve month Return on Invested Capital (ROIC) is 26.93% as of 2026-03-31.